Chantal A Ten Kate1, Dick Tibboel2, Ulrike S Kraemer3. 1. Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center - Sophia Children's Hospital, Postbox 2060, Room Sk-3232, 3000 CB, Rotterdam, The Netherlands. c.tenkate@erasmusmc.nl. 2. Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center - Sophia Children's Hospital, Postbox 2060, Room Sk-3232, 3000 CB, Rotterdam, The Netherlands. d.tibboel@erasmusmc.nl. 3. Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center - Sophia Children's Hospital, Postbox 2060, Room Sk-3232, 3000 CB, Rotterdam, The Netherlands. u.kraemer@erasmusmc.nl.
Abstract
UNLABELLED: Pulmonary hypertension (PH) is a life-threatening disease with a high mortality rate and a broad variety of underlying etiologies. The current golden standard for diagnosing PH and monitoring efficiency of treatment is right heart catheterization. As an alternative, serum biomarkers have been suggested. Cardiac troponin T (TnT), brain natriuretic peptide (BNP), and NT-proBNP seem the most potential. The aim of this systematic review was to evaluate the current literature on the prognostic value of these biomarkers in children with PH and their usefulness as a diagnostic tool. A systematic literature search yielded 14 studies on patients ≤18 years with proven PH with (NT-pro)BNP or TnT as primary outcome. TnT is suggested to be a promising biomarker, but its usefulness in clinical practice has not been proven. The levels of (NT-pro)BNP seemed to be reliable within one PH category, but differed significantly between categories. NT-proBNP showed a good correlation with mortality and might have a prognostic value. CONCLUSION: The lack of absolute levels makes (NT-pro)BNP unsuitable as a diagnostic marker, but in view of the relative changes, it could be used to monitor patients. Further investigation should explore differences in normal (NT-pro)BNP levels between the different categories of PH. WHAT IS KNOWN: • Pulmonary hypertension is a life-threatening disease. Diagnosis can be challenging in children; the current diagnostic options-right heart catheterization and echocardiography-are invasive and/or investigator-dependent procedures. • Biomarkers could be useful in this context because they are investigator independent and easy to obtain through blood samples. Brain natriuretic peptide (BNP) and its N-terminal cleavage product (NT-proBNP) seem to be the most promising. The value of these biomarkers in the diagnostic approach of PH has already been investigated in adults, with promising results. Pediatric studies are still scarce. What is new: • The levels of BNP and NT-proBNP in pediatric patients differ strongly between the different categories of PH. Within the same category, the levels are more or less equal. • The relative changes could render them a prognostic marker in the follow-up of a certain individual patient. At this moment there is not enough evidence to rely on BNP or NT-proBNP in clinical treatment of patients with PH.
UNLABELLED: Pulmonary hypertension (PH) is a life-threatening disease with a high mortality rate and a broad variety of underlying etiologies. The current golden standard for diagnosing PH and monitoring efficiency of treatment is right heart catheterization. As an alternative, serum biomarkers have been suggested. Cardiac troponin T (TnT), brain natriuretic peptide (BNP), and NT-proBNP seem the most potential. The aim of this systematic review was to evaluate the current literature on the prognostic value of these biomarkers in children with PH and their usefulness as a diagnostic tool. A systematic literature search yielded 14 studies on patients ≤18 years with proven PH with (NT-pro)BNP or TnT as primary outcome. TnT is suggested to be a promising biomarker, but its usefulness in clinical practice has not been proven. The levels of (NT-pro)BNP seemed to be reliable within one PH category, but differed significantly between categories. NT-proBNP showed a good correlation with mortality and might have a prognostic value. CONCLUSION: The lack of absolute levels makes (NT-pro)BNP unsuitable as a diagnostic marker, but in view of the relative changes, it could be used to monitor patients. Further investigation should explore differences in normal (NT-pro)BNP levels between the different categories of PH. WHAT IS KNOWN: • Pulmonary hypertension is a life-threatening disease. Diagnosis can be challenging in children; the current diagnostic options-right heart catheterization and echocardiography-are invasive and/or investigator-dependent procedures. • Biomarkers could be useful in this context because they are investigator independent and easy to obtain through blood samples. Brain natriuretic peptide (BNP) and its N-terminal cleavage product (NT-proBNP) seem to be the most promising. The value of these biomarkers in the diagnostic approach of PH has already been investigated in adults, with promising results. Pediatric studies are still scarce. What is new: • The levels of BNP and NT-proBNP in pediatric patients differ strongly between the different categories of PH. Within the same category, the levels are more or less equal. • The relative changes could render them a prognostic marker in the follow-up of a certain individual patient. At this moment there is not enough evidence to rely on BNP or NT-proBNP in clinical treatment of patients with PH.
Authors: Rosa Laura E van Loon; Marcus T R Roofthooft; Hans L Hillege; Arend D J ten Harkel; Magdalena van Osch-Gevers; Tammo Delhaas; Livia Kapusta; Jan L M Strengers; Lukas Rammeloo; Sally-Ann B Clur; Barbara J M Mulder; Rolf M F Berger Journal: Circulation Date: 2011-09-26 Impact factor: 29.690
Authors: Mirjam E Van Albada; Frederieke G Loot; Rebecca Fokkema; Marcus T R Roofthooft; Rolf M F Berger Journal: Pediatr Res Date: 2008-03 Impact factor: 3.756
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir Journal: Pediatr Cardiol Date: 2008-07-04 Impact factor: 1.655
Authors: Martina A Steurer; Anita J Moon-Grady; Jeff R Fineman; Christine E Sun; Leslie A Lusk; Katherine C Wai; Roberta L Keller Journal: Pediatr Res Date: 2014-09-04 Impact factor: 3.756
Authors: Claudio Parolo; Andrea Idili; Gabriel Ortega; Andrew Csordas; Alex Hsu; Netzahualcóyotl Arroyo-Currás; Qin Yang; Brian Scott Ferguson; Jinpeng Wang; Kevin W Plaxco Journal: ACS Sens Date: 2020-07-13 Impact factor: 7.711
Authors: Megan Griffiths; Jun Yang; Catherine E Simpson; Dhananjay Vaidya; Melanie Nies; Stephanie Brandal; Rachel Damico; D Dunbar Ivy; Eric D Austin; Michael W Pauciulo; Katie A Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; William C Nichols; Allen D Everett Journal: Chest Date: 2021-02-18 Impact factor: 10.262
Authors: Erika B Rosenzweig; Steven H Abman; Ian Adatia; Maurice Beghetti; Damien Bonnet; Sheila Haworth; D Dunbar Ivy; Rolf M F Berger Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Rachel K Hopper; Yan Wang; Valerie DeMatteo; Ashley Santo; Steven M Kawut; Okan U Elci; Brian D Hanna; Laura Mercer-Rosa Journal: Pulm Circ Date: 2018-02-26 Impact factor: 3.017